Dysfunction of the endocannabinoid system (ECS) has been identified in metabolic disease. Cannabinoid receptor 1 (CB₁) is abundantly expressed in the brain but also expressed in the periphery. Cannabinoid receptor 2 (CB₂) is more abundant in the periphery, including the immune cells. In obesity, global antagonism of overexpressed CB₁ reduces bodyweight but leads to centrally mediated adverse psychological outcomes. Emerging research in isolated cultured cells or tissues has demonstrated that targeting the endocannabinoid system in the periphery alleviates the pathologies associated with metabolic disease. Further, peripheral specific cannabinoid ligands can reverse aspects of the metabolic phenotype. This Keynote review will focus on current research on the functionality of peripheral modulation of the ECS for the treatment of obesity.

已在代谢性疾病中发现了内源性大麻素系统（ECS）的功能障碍。大麻素受体1（CB ₁）在大脑中大量表达，但在外周组织中也表达。大麻素受体2（CB ₂）在周围包括免疫细胞中含量更高。在肥胖症中，过度拮抗的CB _1具有全球拮抗作用降低体重，但导致中枢介导的不良心理结果。在分离的培养细胞或组织中的新兴研究表明，靶向外周大麻素系统可减轻与代谢疾病相关的病理。此外，外周特异性大麻素配体可以逆转代谢表型的方面。本主题演讲的重点将放在有关ECS周围调节功能治疗肥胖症的当前研究上。